Table III.
Included studies.
| Study | Year | Time | Type of study | Level of evidence | Location | Patients, n | Hips, n | Male, n | Female, n | Mean age, yrs | Follow-up, mths |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Arthroscopy | |||||||||||
| Kunze et al26 | 2020 | Retrospective | Comparative trial | 3 | USA | 310 | 310 | 120 | 190 | 34 | 60 |
| Lindmann et al27 | 2020 | Prospective | Case series | 4 | Sweden | 64 | 84 | 52 | 12 | 24 | 60 |
| Öhlin et al28 | 2020 | Prospective | Case series | 4 | Sweden | 184 | 225 | 110 | 74 | 38 | 60 |
| Ortiz-Declet et al29 | 2020 | Prospective | Case series | 4 | USA | 34 | 34 | 15 | 19 | 20.8 | 47.4 |
| Bolia et al30 | 2019 | Retrospective | Comparative trial | 3 | USA | 99 | 126 | 72 | 54 | 38 | 87.6 (SD 32.4) |
| Hassebrock et al31 | 2019 | Retrospective | Comparative trial | 3 | USA | 133 | 133 | 47 | 86 | 31.96 | 24 |
| Kierkegaard et al32 | 2019 | Prospective | Cohort study with a cross-sectional comparison | 3 | Denmark | 56 | 72 | 24 | 32 | 36 | 12 |
| Perets et al33 | 2019 | Prospective | Case series | 4 | USA | 295 | 327 | 108 | 219 | 32.4 | 68.7 |
| de Girolamo et al34 | 2018 | Retrospective | Comparative trial | 3 | Italy | 109 | 109 | 64 | 54 | 39.3 and 38.3 | 96 |
| Kaldau et al35 | 2018 | Retrospective | Case series | 4 | Denmark | 84 | 84 | 45 | 39 | 40.4 | 82.9 |
| Mansell et al36 | 2018 | Prospective | RCT | 1 | USA | 66 | 66 | 39 | 21 | 30.3 | 24 |
| Tahoun et al37 | 2018 | Prospective | Case series | 4 | Egypt | 23 | 23 | 18 | 5 | 40.9 | 38.4 (SD 7.0) |
| Zimmerer et al38 | 2018 | Prospective | Case series | 4 | Germany | 43 | 43 | 31 | 12 | 25 | 24.4 |
| Menge et al39 | 2017 | Retrospective | Comparative trial | 3 | USA | 154 | 154 | 80 | 74 | 40.6 | 120 |
| Murata et al40 | 2017 | Retrospective | Comparative trial | 3 | Japan | 74 | 74 | 43 | 31 | 28.3 and 39.7 | 24 |
| Tjong et al41 | 2017 | Prospective | Case series | 4 | USA | 86 | 106 | 36 | 50 | 38.1 | 37.2 |
| Degen et al42 | 2016 | Retrospective | Case series | 4 | USA | 70 | 86 | 70 | 0 | 22.5 | 16.8 |
| Hufeland et al43 | 2016 | Retrospective | Case series | 4 | Germany | 44 | 44 | 24 | 20 | 34.3 | 66.3 (SD 14.5) |
| Joseph et al44 | 2016 | Prospective | Cohort study | 2 | USA | 64 | 64 | 19 | 45 | 31.6 and 31.1 | 24 |
| Dippmann et al45 | 2014 | Prospective | Case series | 4 | Denmark | 76 | 76 | 27 | 49 | 38 | 12 |
| Gicquel et al46 | 2014 | Prospective | Case series | 4 | France | 51 | 53 | 19 | 32 | 31 | 55.2 (50.4 to 66) |
| Gupta et al47 | 2014 | Prospective | Case series | 4 | USA | 47 | 47 | 28 | 19 | 37 | 28.32 (24 to 41) |
| Nielsen et al48 | 2014 | Prospective | Case series | 4 | Denmark | 117 | 117 | 48 | 69 | 37 | 40 (24 to 60) |
| Domb et al49 | 2013 | Prospective | Matched-pair comparative study | 2 | USA | 20 | 20 | 4 | 16 | 19.6 | 25.5 |
| Krych et al50 | 2013 | Prospective | RCT | 1 | USA | 36 | 36 | 0 | 36 | 38 and 39 | 32 (12 to 48) |
| Malviya et al51 | 2013 | Prospective | Case series | 4 | UK | 80 | 92 | 50 | 30 | 35.7 | 16.8 (12 to 21.6) |
| Zingg et al52 | 2013 | Prospective | Comparative trial | 3 | Switzerland | 23 | 23 | 18 | 5 | 27.6 | 12 |
| Larson et al53 | 2012 | Prospective | Cohort study | 3 | USA | 90 | 94 | 56 | 38 | 32 and 28 | 42 (24 to 72) |
| Palmer et al54 | 2012 | Prospective | Case series | 4 | USA | 185 | 201 | 99 | 102 | 40.2 | 46 |
| Philippon et al55 | 2012 | Prospective | Case series | 4 | USA | 153 | 153 | 72 | 81 | 57 | 35.7 (12 to 64) |
| Byrd and Jones56 | 2011 | Prospective | Case series | 4 | USA | 200 | 200 | 148 | 52 | 28.6 | 24 |
| Haviv et al57 | 2010 | Retrospective | Case series | 4 | Israel | 166 | 170 | 132 | 34 | 37 | 22 (12 to 72) |
| Horisberger et al58 | 2010 | Prospective | Case series | 4 | Switzerland | 88 | 105 | 60 | 28 | 40.9 | 27.6 (15.6 to 49.2) |
| Philippon et al59 | 2009 | Prospective | Case series | 4 | USA | 112 | 112 | 50 | 62 | 40.6 | 27.6 (24 to 34.8) |
| AMO approach | |||||||||||
| Skowronek et al60 | 2017 | Retrospective | Cohort study | 4 | Poland | 39 | 39 | 25 | 14 | 29.3 | 45 (24 to 55) |
| Ezechieli et al61 | 2016 | Prospective | Comparative trial | 3 | A - Germany B - Italy |
72 | 72 | 38 | 34 | A - 36 B - 28.5 |
15 (6 to 24) |
| Srinivasan et al62 | 2013 | Retrospective | Cohort study | 4 | UK | 25 | 26 | 11 | 15 | 31.3 | 22.3 |
| Chiron et al63 | 2012 | Prospective | Cohort study | 4 | France | 106 | 118 | 92 | 16 | 34.4 | 26.4 (12 to 54) |
| Ribas et al64 | 2010 | Prospective | Cohort study | 4 | Spain | 105 | 107 | 79 | 38 | 37 | 12 |
| Nepple et al65 | 2009 | Retrospective | Comparative trial | 3 | USA | 25 | 25 | 17 | 8 | 33 | 20.4 |
| SHD | |||||||||||
| Kockara et al66 | 2018 | Retrospective | Cohort study | 4 | Turkey | 33 | 34 | 19 | 14 | 34.5 | 72 |
| İnan et al67 | 2016 | Retrospective | Cohort study | 4 | Turkey | 21 | 22 | 7 | 14 | 33.8 | 48 |
| Hingsammer et al68 | 2015 | Retrospective | Cohort study | 4 | Switzerland | 23 | 30 | 18 | 5 | 24.3 | 19.2 (9.6 to 36) |
| Steppacher et al69 | 2014 | Retrospective | Cohort study | 4 | Switzerland | 75 | 97 | 55 | 42 | 32 | 72 (60 to 84) |
| Domb et al49 | 2013 | Prospective | Comparative trial | 3 | USA | 10 | 10 | 2 | 8 | 19 | 24.8 |
| Zingg et al52 | 2013 | Prospective | Comparative trial | 3 | Switzerland | 15 | 15 | 11 | 4 | 28.9 | 12 |
| Jäger et al70 | 2011 | Prospective | Cohort study | 4 | Germany | 21 | 21 | 7 | 15 | 36.3 | 12 |
| Naal et al71 | 2011 | Retrospective | Cohort study | 4 | Switzerland | 22 | 30 | 22 | 0 | 19.7 | 45.1 (12 to 79) |
| Yun et al72 | 2009 | Retrospective | Cohort study | 4 | South Korea | 14 | 15 | 12 | 2 | 35.8 | 27.6 (12 to 120) |
| Espinosa et al73 | 2006 | Retrospective | Comparative trial | 3 | Switzerland | 52 | 60 | 33 | 19 | 30 | 24 |
AMO, anterior mini open approach; RCT, randomized controlled trial; SD, standard deviation; SHD, surgical hip dislocation.